Details zur Publikation |
| Kategorie | Textpublikation |
| Referenztyp | Buchkapitel |
| DOI | 10.1007/978-3-662-04183-3_10 |
| Titel (primär) | The hybrid cell vaccination approach to cancer immunotherapy |
| Titel (sekundär) | Therapeutic vaccination strategies |
| Autor | Trefzer, U.; Herberth, G.
; Sterry, W.; Walden, P. |
| Herausgeber | Walden, P.; Sterry, W.; Hennekes, H. |
| Quelle | Ernst Schering Research Foundation Workshop |
| Erscheinungsjahr | 2000 |
| Department | IMMU |
| Band/Volume | 30 |
| Seite von | 155 |
| Seite bis | 166 |
| Sprache | englisch |
| Abstract | A variety of cancer immunotherapy approaches aim at the induction of cytolytic T lymphocytes (CTLs) as main effector cells in anti-tumor immune responses. However, the mere existence of the tumor proves the failure of immune surveillance and points at immune response defects. Antigenicity is prerequisite for specific immunotherapy and has been proven or is suggested by indirect evidence for several tumors. The failure of the immune system to cope with the cancer in these cases must therefore be attributed to immune regulatory problems including immune suppression, the lack of costimulatory support, or, very importantly, the lack of T cell help for the induction of cytolytic T effector cells. In addition, to become instrumental for clinical application, immunotherapy protocols must be suitable for highly individualized treatments and applicable without lengthy preparations. |
| dauerhafte UFZ-Verlinkung | https://www.ufz.de/index.php?en=20939&ufzPublicationIdentifier=11157 |
| Trefzer, U., Herberth, G., Sterry, W., Walden, P. (2000): The hybrid cell vaccination approach to cancer immunotherapy In: Walden, P., Sterry, W., Hennekes, H. (eds.) Therapeutic vaccination strategies Ernst Schering Research Foundation Workshop 30 Springer, Berlin, Heidelberg, p. 155 - 166 10.1007/978-3-662-04183-3_10 |
|